Clinical Trials Logo

Myasthenia Gravis, MuSK clinical trials

View clinical trials related to Myasthenia Gravis, MuSK.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06414954 Not yet recruiting - Myasthenia Gravis Clinical Trials

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

SYNAPSE-MG
Start date: May 2024
Phase: Phase 2
Study type: Interventional

This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.